Company Description
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3.
The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases.
The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 27, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 730 |
| CEO | Neil Kumar |
Contact Details
Address: 3160 Porter Drive, Suite 250 Palo Alto, California 94304 United States | |
| Phone | 650 391 9740 |
| Website | bridgebio.com |
Stock Details
| Ticker Symbol | BBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001743881 |
| CUSIP Number | 10806X102 |
| ISIN Number | US10806X1028 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric Michael David J.D., M.D., Ph.D. | Chief Executive Officer of Gene Therapy |
| Dr. Neil Kumar Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Dr. Charles J. Homcy M.D. | Co-Founder, Chairman of Pharmaceuticals and Independent Lead Director |
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Chairman of Oncology and Director |
| Dr. Richard H. Scheller Ph.D. | Chairman of Research and Development |
| Dr. Thomas Trimarchi Ph.D. | Chief Financial Officer and President |
| Maricel M. Apuli | Chief Accounting Officer |
| Dr. Uma Sinha Ph.D. | Chief Scientific Officer |
| Eli M. Wallace Ph.D. | Chief Scientific Officer of Oncology |
| Matthew Outten CPC, MBA | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 14, 2025 | 144 | Filing |
| Apr 2, 2025 | 144 | Filing |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 12, 2025 | SCHEDULE 13D/A | Filing |
| Mar 7, 2025 | SCHEDULE 13D/A | Filing |
| Mar 6, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Feb 28, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 144 | Filing |